Clinical Report: Efficacy and Safety of DLL3-Targeted CAR-T Therapy
Background
Extensive-stage small-cell lung cancer (ES-SCLC) is associated with a poor prognosis and limited treatment options. LB2102 is an investigational CAR-T cell therapy designed to target DLL3, a protein highly expressed in SCLC, while minimizing toxicity to normal tissues.
Data Highlights
No numerical data available.
Key Findings
The patient had a high DLL3 expression score (≥2+) in 88% of tumor biopsy specimens.
After receiving LB2102, the patient tolerated the infusion without dose-limiting toxicity or cytokine release syndrome.
By week 12 post-infusion, the target lesion had shrunk by 35%, indicating a partial response.
Post-treatment imaging showed stable metastatic disease and no liver lesions.
Cytopenias observed post-infusion recovered without intervention by week 10.
Clinical Implications
The case presents LB2102 as a treatment option for patients with recurrent ES-SCLC who are ineligible for clinical trials.
Conclusion
This case study presents the use of DLL3-targeted CAR-T therapy in a patient with recurrent ES-SCLC.
by Chelsey M. Williams, Susanne M. Arnold, John L. Villano, Erika N. Amarilla Alonso, Christine F. Brainson, Paul O. Schwarzenberger, Sahista Vahora, Ayman Qasrawi, Reinhold Munker, B. Mark Evers, Zhonglin Hao
